FAILED
首站-论文投稿智能助手
典型文献
Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation:A new platform for synergistic oncology therapy
文献摘要:
Although multifarious tumor-targeting modifications of nanoparticulate systems have been at-tempted in joint efforts by our predecessors,it remains challenging for nanomedicine to traverse physiolog-ical barriers involving blood vessels,tissues,and cell barriers to thereafter demonstrate excellent antitumor effects.To further overcome these inherent obstacles,we designed and prepared mycoplasma membrane(MM)-fused liposomes(LPs)with the goal of employing circulating neutrophils with the advantage of in-flammatory cytokine-guided autonomous tumor localization to transport nanoparticles.We also utilized in vivo neutrophil activation induced by the liposomal form of the immune activator resiquimod(LPs-R848).Fused LPs preparations retained mycoplasma pathogen characteristics and achieved rapid recogni-tion and endocytosis by activated neutrophils stimulated by LPs-R848.The enhanced neutrophil infiltration in homing of the inflammatory tumor microenvironment allowed more nanoparticles to be delivered into solid tumors.Facilitated by the formation of neutrophil extracellular traps(NETs),podophyllotoxin(POD)-loaded MM-fused LPs(MM-LPs-POD)were concomitantly released from neutrophils and subse-quently engulfed by tumor cells during inflammation.MM-LPs-POD displayed superior suppression effi-cacy of tumor growth and lung metastasis in a 4T1 breast tumor model.Overall,such a strategy of pathogen-mimicking nanoparticles hijacking neutrophils in situ combined with enhanced neutrophil infiltra-tion indeed elevates the potential of chemotherapeutics for tumor targeting therapy.
文献关键词:
作者姓名:
Xiaobei Cheng;Pei Yu;Xiang Zhou;Jiale Zhu;Yubao Han;Chao Zhang;Lingyi Kong
作者机构:
State Key Laboratory of Natural Medicines,Jiangsu Key Laboratory of Bioactive Natural Product Research,School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 210009,China;Department of Science,China Pharmaceutical University,Nanjing 210009,China
引用格式:
[1]Xiaobei Cheng;Pei Yu;Xiang Zhou;Jiale Zhu;Yubao Han;Chao Zhang;Lingyi Kong-.Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation:A new platform for synergistic oncology therapy)[J].药学学报(英文版),2022(02):924-938
A类:
nanoparticulate,predecessors,resiquimod,Facilitated,podophyllotoxin
B类:
Enhanced,homing,pathogen,mimicking,liposomes,driven,by,R848,stimulation,new,platform,synergistic,oncology,therapy,Although,multifarious,targeting,modifications,systems,have,been,tempted,joint,efforts,our,remains,challenging,nanomedicine,traverse,physiolog,ical,barriers,involving,blood,vessels,tissues,thereafter,demonstrate,excellent,antitumor,effects,To,further,overcome,these,inherent,obstacles,designed,prepared,mycoplasma,membrane,MM,fused,LPs,goal,employing,circulating,neutrophils,advantage,cytokine,guided,autonomous,localization,transport,nanoparticles,We,also,utilized,vivo,activation,induced,liposomal,immune,activator,Fused,preparations,retained,characteristics,achieved,rapid,recogni,endocytosis,activated,stimulated,enhanced,infiltration,inflammatory,microenvironment,allowed,more,delivered,into,solid,tumors,formation,extracellular,traps,NETs,POD,loaded,were,concomitantly,released,from,subse,quently,engulfed,cells,during,inflammation,displayed,superior,suppression,effi,cacy,growth,lung,metastasis,4T1,breast,model,Overall,such,strategy,hijacking,situ,combined,indeed,elevates,potential,chemotherapeutics
AB值:
0.620485
相似文献
Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-αinduced by urotensin Ⅱ
Jun LI;Limin LUO;Yonggang ZHANG;Xiao DONG;Shuyi DANG;Xiaogang GUO;Wenhui DING-Department of Cardiology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Division of Cardiology,Department of Internal Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,China;Division of Cardiology,Department of Internal Medicine,Peking University First Hospital,Beijing 100034,China;Department of Dermatology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Cardiovascular Diseases,the Second Affiliated Hospital,Shantou University Medical College,Shantou 515041,China
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β
Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan-Shanghai Institute of Hematology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;VIP Health Center,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China;Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Targeting the Rac1 pathway for improved prostate cancer therapy using polymeric nanoparticles to deliver of NSC23766
Zean Li;Jun Huang;Tao Du;Yiming Lai;Kaiwen Li;Man-Li Luo;Dingjun Zhu;Jun Wu;Hai Huang-Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510220,China;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Medical Research Center,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;School of Biomedical Engineering,Sun Yat-sen University,Shenzhen 518107,China;Department of Obstetrics and Gynecology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Urology,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China
Supramolecular engineering of cell membrane vesicles for cancer immunotherapy
Shaolong Qi;Haiyan Zhang;Xueyan Zhang;Xinyang Yu;Yajun Wang;Qian-Fang Meng;Kai Yang;Bing Bai;Rui Tian;Shoujun Zhu;Lang Rao;Feihe Huang;Guocan Yu-Key Laboratory of Bioorganic Phosphorus Chemistry&Chemical Biology,Department of Chemistry,Tsinghua University,Beijing 100084,China;State Key Laboratory of Supramolecular Structure and Materials,College of Chemistry,Jilin University,Changchun 130012,China;Institute of Biomedical Health Technology and Engineering,Shenzhen Bay Laboratory,Shenzhen 518132,China;State Key Laboratory of Chemical Engineering,Stoddart Institute of Molecular Science,Department of Chemistry,Zhejiang University,Hangzhou 310027,China;ZJU-Hangzhou Global Scientific and Technological Innovation Center,Hangzhou 311215,China;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,Center for Molecular Imaging and Translational Medicine School of Public Health,Xiamen University,Xiamen 361102,China
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
Jingjing He;Xinxin Xiong;Han Yang;Dandan Li;Xuefei Liu;Shuo Li;Shuangye Liao;Siyu Chen;Xizhi Wen;Kuai Yu;Lingyi Fu;Xingjun Dong;Kaiyu Zhu;Xiaojun Xia;Tiebang Kang;Chaochao Bian;Xiang Li;Haiping Liu;Peirong Ding;Xiaoshi Zhang;Zhenjiang Liu;Wende Li;Zhixiang Zuo;Penghui Zhou-State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou,China;Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;Guangdong Laboratory Animals Monitoring Institute,Guangdong Key Laboratory of Laboratory Animals,Guangzhou,China;Guangzhou Finelmmune Biotechnology Co.,LTD,Guangzhou,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。